HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of chelating agents as anti-angiogenic therapy through copper chelation.

Abstract
The evaluation of several sets of polyamine donor chelating agents including a selection of novel hexadentate 1,3,5-cis,cis-triaminocyclohexane (tach) based derivatives were performed in an in vitro endothelial cell proliferation assay to assess their cytotoxicity and selectivity as novel anti-angiogenic agents. The selective nature of the anti-angiogenic agents for human umbilical vein endothelial cells (HUVEC) was compared to a normal fibroblast cell line and a human Glioma cell line to evaluate these compounds. Linear tri- and tetra-polyamines were superior to both macrocyclic and the tach based polyamine chelating agents in terms of selectivity of its inhibitory activity toward the proliferation of HUVEC cells compared to the fibroblast and human Glioma cells. The linear polyamine, triethylenetetramine (22), previously reported to possess anti-angiogenic properties failed to demonstrate any selectivity for inhibiting the proliferation of HUVEC cells compared to the fibroblast and human Glioma cells.
AuthorsKevin Camphausen, Mary Sproull, Steve Tantama, Vincent Venditto, Sandeep Sankineni, Tamalee Scott, Martin W Brechbiel
JournalBioorganic & medicinal chemistry (Bioorg Med Chem) Vol. 12 Issue 19 Pg. 5133-40 (Oct 01 2004) ISSN: 0968-0896 [Print] England
PMID15351396 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Chelating Agents
  • Polyamines
  • Copper
Topics
  • Angiogenesis Inhibitors (chemistry, pharmacology)
  • Cell Line
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cells, Cultured
  • Chelating Agents (chemistry, pharmacology)
  • Copper (chemistry)
  • Endothelial Cells (cytology, drug effects)
  • Fibroblasts (cytology)
  • Glioma (pathology)
  • Humans
  • Polyamines (chemistry, pharmacology)
  • Structure-Activity Relationship
  • Umbilical Veins (cytology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: